OA07820A - 2,5-Disubstituées-4(3H)-pyrimidones ayant une activité antagoniste réceptrice histamine H2, et compositions pharmaceutiques contenant de tels composés à titre d'ingrédients actifs. - Google Patents
2,5-Disubstituées-4(3H)-pyrimidones ayant une activité antagoniste réceptrice histamine H2, et compositions pharmaceutiques contenant de tels composés à titre d'ingrédients actifs.Info
- Publication number
- OA07820A OA07820A OA58396A OA58396A OA07820A OA 07820 A OA07820 A OA 07820A OA 58396 A OA58396 A OA 58396A OA 58396 A OA58396 A OA 58396A OA 07820 A OA07820 A OA 07820A
- Authority
- OA
- OAPI
- Prior art keywords
- pyrimidones
- histamine
- disubstituted
- compounds
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/534,426 US4772704A (en) | 1983-09-21 | 1983-09-21 | 2,5-disubstituted-4(3H)-pyrimidones having histamine H2 -receptor antagonist activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA07820A true OA07820A (fr) | 1986-11-20 |
Family
ID=24129972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA58396A OA07820A (fr) | 1983-09-21 | 1984-09-20 | 2,5-Disubstituées-4(3H)-pyrimidones ayant une activité antagoniste réceptrice histamine H2, et compositions pharmaceutiques contenant de tels composés à titre d'ingrédients actifs. |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US4772704A (es) |
| JP (1) | JPH0643310B2 (es) |
| KR (1) | KR900001198B1 (es) |
| AR (2) | AR242385A1 (es) |
| AT (1) | AT387965B (es) |
| AU (1) | AU583479B2 (es) |
| BE (1) | BE900652A (es) |
| CA (1) | CA1260463A (es) |
| CH (1) | CH665840A5 (es) |
| CS (1) | CS249147B2 (es) |
| CY (1) | CY1561A (es) |
| DD (1) | DD226881A5 (es) |
| DE (1) | DE3434578A1 (es) |
| DK (1) | DK162987C (es) |
| ES (4) | ES8607253A1 (es) |
| FI (1) | FI83868C (es) |
| FR (1) | FR2552082B1 (es) |
| GB (1) | GB2146994B (es) |
| GR (1) | GR80439B (es) |
| HK (1) | HK73790A (es) |
| HU (1) | HU193227B (es) |
| IE (1) | IE58083B1 (es) |
| IL (1) | IL72990A (es) |
| IT (1) | IT1176739B (es) |
| LU (1) | LU85550A1 (es) |
| NL (1) | NL8402898A (es) |
| NO (1) | NO161561C (es) |
| NZ (1) | NZ209572A (es) |
| OA (1) | OA07820A (es) |
| PT (1) | PT79256B (es) |
| SE (1) | SE463209B (es) |
| SG (1) | SG60890G (es) |
| YU (1) | YU45205B (es) |
| ZA (1) | ZA847345B (es) |
| ZM (1) | ZM4984A1 (es) |
| ZW (1) | ZW16084A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2873340B2 (ja) * | 1988-04-29 | 1999-03-24 | 武田薬品工業株式会社 | 抗生物質ｔａｎ―１０５７，その製造法および用途 |
| WO2022034121A1 (en) | 2020-08-11 | 2022-02-17 | Université De Strasbourg | H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN151188B (es) * | 1978-02-13 | 1983-03-05 | Smith Kline French Lab | |
| ES477520A1 (es) * | 1978-02-25 | 1979-06-01 | Thomae Gmbh Dr K | Procedimiento para la preparacion de nuevas penicilinas. |
| AU527202B2 (en) * | 1978-04-11 | 1983-02-24 | Smith Kline & French Laboratories Limited | 2-aminopyrimidones |
| US4496567A (en) * | 1978-11-13 | 1985-01-29 | Smith Kline & French Laboratories Limited | Phenyl alkylaminopyrimidones |
| US4521418A (en) * | 1979-02-21 | 1985-06-04 | Smith Kline & French Laboratories Limited | Guanidinothiazolyl derivatives |
| AU531142B2 (en) * | 1979-04-04 | 1983-08-11 | Smith Kline & French Laboratories Limited | 2 amino- pyimindones |
| CA1140129A (en) * | 1979-08-21 | 1983-01-25 | Ronald J. King | 4-pyrimidone derivatives |
| ZW21281A1 (en) * | 1980-10-01 | 1981-11-18 | Smith Kline French Lab | Amine derivatives |
| US4352933A (en) * | 1981-02-06 | 1982-10-05 | Smithkline Beckman Corporation | Chemical methods and intermediates for preparing substituted pyrimidinones |
| CA1206151A (en) * | 1981-12-28 | 1986-06-17 | Richard P. Pioch | Pyrimidone anti-ulcer agents |
| US4468399A (en) * | 1981-12-28 | 1984-08-28 | Eli Lilly And Company | 2-[2-(2-Aminoalkyl-4-thiazolylmethylthio)alkyl]-amino-5-substituted-4-pyrimidones |
| GB8320505D0 (en) * | 1983-07-29 | 1983-09-01 | Smith Kline French Lab | Chemical compounds |
| CA1275097A (en) * | 1984-10-02 | 1990-10-09 | Fujio Nohara | Pyridyloxy derivatives |
-
1983
- 1983-09-21 US US06/534,426 patent/US4772704A/en not_active Expired - Fee Related
-
1984
- 1984-09-17 NZ NZ209572A patent/NZ209572A/en unknown
- 1984-09-18 FI FI843643A patent/FI83868C/fi not_active IP Right Cessation
- 1984-09-18 ZA ZA847345A patent/ZA847345B/xx unknown
- 1984-09-18 IL IL72990A patent/IL72990A/xx not_active IP Right Cessation
- 1984-09-18 ZW ZW160/84A patent/ZW16084A1/xx unknown
- 1984-09-18 ZM ZM49/84A patent/ZM4984A1/xx unknown
- 1984-09-19 NO NO843726A patent/NO161561C/no unknown
- 1984-09-19 CA CA000463533A patent/CA1260463A/en not_active Expired
- 1984-09-19 ES ES536054A patent/ES8607253A1/es not_active Expired
- 1984-09-19 YU YU1613/84A patent/YU45205B/xx unknown
- 1984-09-20 IT IT22744/84A patent/IT1176739B/it active
- 1984-09-20 JP JP59195868A patent/JPH0643310B2/ja not_active Expired - Lifetime
- 1984-09-20 GB GB08423863A patent/GB2146994B/en not_active Expired
- 1984-09-20 HU HU843539A patent/HU193227B/hu not_active IP Right Cessation
- 1984-09-20 DK DK450484A patent/DK162987C/da active
- 1984-09-20 AU AU33351/84A patent/AU583479B2/en not_active Ceased
- 1984-09-20 SE SE8404729A patent/SE463209B/sv not_active IP Right Cessation
- 1984-09-20 CH CH4510/84A patent/CH665840A5/de not_active IP Right Cessation
- 1984-09-20 FR FR8414463A patent/FR2552082B1/fr not_active Expired
- 1984-09-20 DE DE19843434578 patent/DE3434578A1/de not_active Withdrawn
- 1984-09-20 CS CS847103A patent/CS249147B2/cs unknown
- 1984-09-20 OA OA58396A patent/OA07820A/xx unknown
- 1984-09-20 IE IE240684A patent/IE58083B1/en not_active IP Right Cessation
- 1984-09-21 LU LU85550A patent/LU85550A1/fr unknown
- 1984-09-21 KR KR1019840005791A patent/KR900001198B1/ko not_active IP Right Cessation
- 1984-09-21 AR AR84298041A patent/AR242385A1/es active
- 1984-09-21 AT AT0300984A patent/AT387965B/de not_active IP Right Cessation
- 1984-09-21 DD DD84267496A patent/DD226881A5/de not_active IP Right Cessation
- 1984-09-21 PT PT79256A patent/PT79256B/pt not_active IP Right Cessation
- 1984-09-21 GR GR80439A patent/GR80439B/el unknown
- 1984-09-21 NL NL8402898A patent/NL8402898A/nl not_active Application Discontinuation
- 1984-09-21 BE BE0/213705A patent/BE900652A/fr not_active IP Right Cessation
-
1985
- 1985-06-14 ES ES544213A patent/ES8704465A1/es not_active Expired
-
1986
- 1986-01-31 ES ES551500A patent/ES8704155A1/es not_active Expired
- 1986-01-31 ES ES551501A patent/ES8702897A1/es not_active Expired
-
1987
- 1987-09-18 AR AR87308766A patent/AR242789A1/es active
-
1990
- 1990-07-21 SG SG608/90A patent/SG60890G/en unknown
- 1990-09-20 HK HK737/90A patent/HK73790A/xx unknown
-
1991
- 1991-03-22 CY CY1561A patent/CY1561A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL190757C (nl) | 4-(3-Chloorfenyl)-1-piperazinylpropyl gesubstitueerde-1,2,4-triazool-3-on verbindingen met antidepressieve werking en farmaceutische preparaten daarvan. | |
| MC1915A1 (fr) | Procédés pour la préparation de 2',3'-didésoxynucléosides et de formulations pharmaceutiques en contenant | |
| IT1190824B (it) | Composizione farmaceutica contenente 24,25-diidrossicolecalciferolo come ingrediente attivo | |
| IT8324430A0 (it) | Attivita' antitosse e sedativa composti otticamente attivi ad centrale, procedimento per la loro preparazione e composizioni che licontengono. | |
| IL65802A (en) | 1-(3-fluoro-2-pyridinyl)piperazine and salts thereof,their preparation and pharmaceutical compositions containing them | |
| IT1213173B (it) | Composti ad attivita'antibatterica, procedimento per laloro preparazione e relative composizioni farmaceutiche. | |
| OA07820A (fr) | 2,5-Disubstituées-4(3H)-pyrimidones ayant une activité antagoniste réceptrice histamine H2, et compositions pharmaceutiques contenant de tels composés à titre d'ingrédients actifs. | |
| FR2500753B1 (fr) | Glycoproteine ayant une activite biologique, procede pour la preparer et compositions pharmaceutiques immunoactives la contenant | |
| ES2000714A6 (es) | Un procedimiento para preparar derivados de tetrahidroisoquinoleina | |
| IT8322045A0 (it) | Per la loro preparazione e oligosaccaridi eterogenei relative composizioni complessabili ed alfa -idosani ad farmaceutiche. attivita' terapeutica, procedimento | |
| IT8219486A0 (it) | Nuovi composti ad attivita'antiinfiammatoria, procedimento per la loro preparazione e relative composizioni farmaceutiche. | |
| OA08630A (fr) | Fraction immunogène active à l'égard des bilharzioses, sa préparation, compositions immunisantes la contenant. | |
| IT8521528A0 (it) | Composizioni farmaceutiche e cosmetiche contenenti come ingrediente attivo diidrossi-1,8fenil-10 antrone-9, e procedimentodi preparazione dell'ingrediente attivo. | |
| IT8419372A0 (it) | Composto ad attivita' calcio antagonista periferica, anticonvulsivante ed eumetabolica cerebrale,metodo per la sua preparazione e composizioni farmaceutiche. | |
| FR2751967B1 (fr) | Agents antipaludeens et antibabesioses et compositions pharmaceutiques les contenant | |
| IT8119081A0 (it) | Composti macrolidici ad attivita'antibiotica,procedimento e microorganismo per la loro preparazione e relative composizioni farmaceutiche | |
| IT8422257A0 (it) | Miscela di composti diastereoisomeri, ottenuti da (-)-5-(1-idrossi-1-metiletil)-2-metil-2-cicloesen-1-one, avente attivita' mucosecretolitica, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono. | |
| IT8125298A0 (it) | Composto ad attivita'antiinfiammatoria, disinfettante e antibatterica, procedimento per lasua preparazione e relative composizioni farmaceutiche. | |
| IT8520514A0 (it) | Composizioni di farmaci dotate di attivita' antimicrobica eprocedimento per la loro preparazione. | |
| FR2567756B1 (fr) | Nouvelles compositions pharmaceutiques contenant comme ingredient actif l'acetyl-10 triacetoxy-1,8,9 anthracene | |
| IT8321044A0 (it) | Per la loro preparazione e relative composti idrossiminici e composizioni farmaceutiche. alcossiminici ad attivita'calcio-antagonista, procedimento | |
| IT8619383A0 (it) | Nuovi composti ad attivita'colinergica, procedimento per laloro preparazione e relative composizioni farmaceutiche. | |
| FR2691630B1 (fr) | Composition pharmaceutique, en particulier pour l'administration orale, contenant, comme ingrédient actif, un agoniste sélectif des récepteurs de type 5HT1. | |
| IT8121620A0 (it) | Broncosecretolitica e composto ad attivita'antitussigena, procedimenti per lasua preparazione e relative composizioni farmaceutiche. | |
| IT8221679A0 (it) | Composti idrossiminici e alcossiminici ad attivita'calcioantagonista, procedimento per la loro preparazione e relative composizioni farmaceutiche. |